|
|
|
|
||
Re: Approved 2 days early!!!! FDA Expands Indication for REVLIMID® as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)I could be way off base here, but I'm thinking I read someplace recently that this decision would increase revenues about 400 million annually just here in the U.S.. Anyone remember a number out there? |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
209214 | Re: Approved 2 days early!!!! FDA Expands Indication for REVLIMID® as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) | nonmargin | 1 | 2/22/2017 5:01:56 PM |